Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

M. Di Bartolomeo, M. Niger, F. Morano, S. Corallo, M. Antista, S. Tamberi, S. Lonardi, S. Di Donato, R. Berardi, M. Scartozzi, G.G. Cardellino, F. Di Costanzo, L. Rimassa, A.G. Luporini, R. Longarini, A. Zaniboni, A. Bertolini, G. Tomasello, G. Pinotti, G. ScagliottiG. Tortora, A. Bonetti, A. Spallanzani, G.L. Frassineti, D. Tassinari, F. Giuliani, S. Cinieri, E. Maiello, C. Verusio, S. Bracarda, V. Catalano, M. Basso, L. Ciuffreda, F. De Vita, H.S. Parra, L. Fornaro, M. Caporale, F. De Braud, F. Pietrantonio

Research output: Contribution to journalArticle

Original languageItalian
JournalBMC Cancer
Volume19
Issue number1
DOIs
Publication statusPublished - 2019

Cite this